Although the risk of malignancy using anti-TNF agents was observed in RA in the past (especially for lymphomas) [39,40], our study did not find any significant effect for anti-TNF therapy on malignancies in the AS population with anti-TNF-naïve patients (OR 1.25, 95% CI 0.91–1.6). The gene discussed is TNF; the disease is lymphoma.